DoD Kidney Cancer, Idea Development Award | W81XWH 21 KCRP IDA

Opportunity Information: Apply for W81XWH 21 KCRP IDA

The FY21 DoD Kidney Cancer Research Program (KCRP) Idea Development Award is a research funding opportunity designed to push kidney cancer science forward through genuinely innovative, high-impact projects that align with the program's long-term vision of eliminating kidney cancer. It is aimed at supporting new ideas and bold approaches that are still grounded in solid evidence, with proposals expected to present a clear, testable hypothesis backed by a strong scientific rationale and an organized, realistic research plan. The program places a heavy emphasis on the quality and credibility of the proposed research approach, including whether the applicant team demonstrates deep understanding of kidney cancer biology and clinical challenges, and whether the project is positioned to produce outcomes that meaningfully advance the field rather than small, incremental gains.

A central theme of this award is that creativity must be paired with rigor. Applications are expected to lay out feasible experimental designs, clearly explain how goals will be met within the period of performance, and show that necessary resources are available, with documentation to support access to key infrastructure, cohorts, datasets, or specialized technologies. Strong applications are also expected to anticipate practical issues by identifying likely problems and pitfalls and proposing alternate approaches. When applicable, proposals should include a statistical analysis plan and power analysis to justify study design decisions and sample sizes. Preliminary data are required for submission, but they do not have to be kidney cancer-specific. The program allows preliminary support from a PI's or collaborator's prior work, whether unpublished or published, and relevant published literature can also help support feasibility and rationale.

Innovation is treated as a defining requirement rather than a bonus. The award is meant for research that introduces new paradigms, challenges existing ones, or reframes persistent problems in kidney cancer from new angles. High-risk/high-reward concepts are welcome, as long as the application makes a convincing case that success would translate into substantial impact on kidney cancer research directions, patient care, and/or quality of life. By design, projects that are expected to produce only incremental progress are not considered responsive to the spirit of this mechanism. Impact is evaluated in terms of whether the work tackles a central, critical issue in kidney cancer research or clinical care, and whether successful results would significantly advance methods or concepts within one or more FY21 KCRP Focus Areas.

The opportunity is open to both Established Investigators (EIs) and Early-Career Investigators (ECIs) serving as Principal Investigator (PI), and the program specifically signals interest in funding one or more highly meritorious applications led by an ECI. Personnel and team strength are treated as a crucial element of the application. Investigators are expected to demonstrate kidney cancer expertise through the PI's track record, the assembled research team, and/or documented collaborations. An EI is defined as an independent investigator at or above Assistant Professor (or equivalent) who is 10 years or more from completion of a terminal degree, with kidney cancer experience evidenced by publications and funding. An ECI is defined as an independent investigator at the Assistant Professor, Instructor, or Assistant Research Professor level (or equivalent) who is less than 10 years from their terminal degree at the time of the submission deadline, with specific allowances for excluding time in medical residency or family medical leave (but not postdoctoral time). Postdoctoral fellows are explicitly not eligible for ECI designation. For ECIs, the application must also show institutional commitment beyond money, such as protected research time, independent lab space, and collaboration opportunities, and it must include a required Career Development Plan and identify a Career Guide.

The Career Guide requirement is specific and structured. The ECI must designate a Career Guide who will provide career guidance and support in the context of the project. This individual must be at or above the Associate Professor level (or equivalent), must have a demonstrated record of kidney cancer research productivity and/or intellectual property and funding, and must provide a letter of support. In review, ECIs are assessed using different personnel criteria than established investigators, reflecting the program's intent to support strong early-stage independent researchers while still requiring a clear demonstration that the team can execute the proposed research.

In terms of what kinds of projects fit, the announcement highlights several appropriate scopes. Across all applications, the program supports innovative, high-risk/high-reward and/or preclinical research that is supported by preliminary and/or published data. Two special options allow for larger budgets when justified by added complexity and resource demands. The Early Detection Studies Option supports basic or preclinical work focused on biomarkers, improved imaging, and/or new technologies that could change how kidney cancer is detected earlier, and it allows higher funding in recognition that early detection research can require human subjects and/or human biospecimens. The Population Science and Prevention Studies Option supports preclinical population-based research, epidemiology, or public health work that is backed by substantial preliminary or published data and that strongly validates a path toward clinical translation in a well-defined kidney cancer context; this option also allows higher funding with compelling justification, again acknowledging the resource needs that often come with human subjects or biospecimen use. Use of data and/or biospecimens from active-duty Service Members and/or Veterans is encouraged, reflecting the program's military relevance. Human subjects research and research with human anatomical substances are permitted, but clinical trials are not allowed under this opportunity. Across all proposals, relevance is required to active-duty Service Members, Veterans, military beneficiaries, and/or the broader American public.

Awards under this program are issued as assistance agreements, meaning they may be made either as grants or cooperative agreements depending on anticipated DoD involvement. If no substantial involvement by the funding agency is expected, the award is typically a grant; if substantial involvement is anticipated, the award will be a cooperative agreement and will spell out the nature of that involvement, which could include collaboration, participation, or intervention during performance. The funding opportunity also points applicants to recommendations from the congressionally mandated Metastatic Cancer Task Force, encouraging proposals that address those recommendations as long as they fit within the announcement's limits and FY21 KCRP priorities. The program strongly encourages collaborations between military or Veteran institutions and non-military institutions to leverage complementary strengths such as infrastructure and access to unique clinical populations.

From a budgeting standpoint, the anticipated direct cost cap for the standard Idea Development Award is up to $600,000 for the entire period of performance. Under the Early Detection Studies Option, the cap increases to $650,000 in direct costs, and under the Population Science and Prevention Studies Option the cap can be as high as $2,000,000 in direct costs, reflecting the larger scale often required for those study types. The DoD planned to allocate approximately $15.76 million total to fund about 14 awards, with actual funding dependent on federal fund availability, the number of applications received, and the outcome of scientific peer review and programmatic review. The opportunity was released by the Department of Defense (U.S. Army Medical Research Acquisition Activity) under Funding Opportunity Number W81XWH-21-KCRP-IDA, with an original application closing date of October 5, 2021, and awards expected to be made no later than September 30, 2022. Funds were anticipated to be FY21 appropriations, available for use until they expire on September 30, 2027.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Kidney Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 23, 2021.
• Applicants must submit their applications by Oct 05, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 14 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 KCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: